Caution Advised for Surging Biotech Stocks Moderna and Iovance Biotherapeutics
MRK Merck & Co Inc
$144.46 -2.23%
View chart & analysis → - 1Moderna's stock price has risen 570% this year, but its $77 billion market capitalization appears excessive.
- 2Iovance Biotherapeutics recorded Q2 revenue of $99 million, growing nearly 66% compared to last year.
- 3Uncertainty remains despite Iovance Biotherapeutics' stock price rising 433% this year.
So what's the key point?
The stock prices of Moderna and Iovance Biotherapeutics have risen significantly this year. However, caution is needed due to high company valuations or existing uncertainties.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.